NZ703225A - Superior efficacy of cd37 antibodies in cll blood samples - Google Patents

Superior efficacy of cd37 antibodies in cll blood samples

Info

Publication number
NZ703225A
NZ703225A NZ703225A NZ70322511A NZ703225A NZ 703225 A NZ703225 A NZ 703225A NZ 703225 A NZ703225 A NZ 703225A NZ 70322511 A NZ70322511 A NZ 70322511A NZ 703225 A NZ703225 A NZ 703225A
Authority
NZ
New Zealand
Prior art keywords
antibodies
blood samples
superior efficacy
cll blood
cll
Prior art date
Application number
NZ703225A
Other languages
English (en)
Inventor
Stephan Stilgenbauer
Karl-Heinz Heider
Thorsten Zenz
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44546328&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ703225(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NZ703225A publication Critical patent/NZ703225A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NZ703225A 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples NZ703225A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10169795 2010-07-16
EP10175586 2010-09-07
NZ603161A NZ603161A (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples

Publications (1)

Publication Number Publication Date
NZ703225A true NZ703225A (en) 2016-11-25

Family

ID=44546328

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ703225A NZ703225A (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples
NZ603161A NZ603161A (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ603161A NZ603161A (en) 2010-07-16 2011-07-15 Superior efficacy of cd37 antibodies in cll blood samples

Country Status (15)

Country Link
US (3) US20120189618A1 (enExample)
EP (2) EP2593479A1 (enExample)
JP (2) JP2013538790A (enExample)
KR (1) KR20130100918A (enExample)
CN (2) CN105749276A (enExample)
AU (1) AU2011278227B2 (enExample)
BR (1) BR112013001012A2 (enExample)
CA (1) CA2799036A1 (enExample)
CL (1) CL2013000101A1 (enExample)
EA (1) EA025365B1 (enExample)
IL (1) IL222775A (enExample)
MX (1) MX341463B (enExample)
NZ (2) NZ703225A (enExample)
PH (1) PH12013500118A1 (enExample)
WO (1) WO2012007576A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
US20130287797A1 (en) * 2012-04-26 2013-10-31 Boehringer Ingelheim International Gmbh Combination of cd37 antibodies with bendamustine
EP2849784A1 (en) 2012-05-16 2015-03-25 Boehringer Ingelheim International GmbH Combination of cd37 antibodies with ice (ifosfamide, carboplatin, etoposide)
SG11201707089WA (en) * 2015-04-13 2017-10-30 Pfizer Chimeric antigen receptors targeting b-cell maturation antigen
WO2018132506A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Chimeric antigen receptors based on alternative signal 1 domains
AU2018236450A1 (en) 2017-03-16 2019-10-03 The General Hospital Corporation Chimeric antigen receptors targeting CD37
UA127586C2 (uk) 2017-03-31 2023-10-25 Ґенмаб Холдінґ Б.В. Біспецифічні анти-cd37-антитіла, моноклональні анти-cd37-антитіла та способи їх застосування
US12275797B2 (en) 2018-06-22 2025-04-15 Genmab Holding B.V. Anti-CD37 antibodies and anti-CD20 antibodies, compositions and methods of use thereof
MA53812A (fr) 2018-10-04 2021-08-11 Genmab Holding B V Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
EP4412715A1 (en) 2021-10-06 2024-08-14 Nordic Nanovector ASA Humanized hh1
WO2023057595A1 (en) 2021-10-06 2023-04-13 Nordic Nanovector Asa Humanized hh1 rew
WO2025083205A1 (en) 2023-10-18 2025-04-24 Debiopharm International S.A. Drug combination comprising anti-cd37 antibody maytansine conjugate and bcl2 inhibitor or pi3k inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
SG10201403526YA (en) * 2005-07-25 2014-10-30 Emergent Product Dev Seattle B-cell reduction using cd37-specific and cd20-specific binding molecules
JP2010532764A (ja) * 2007-07-06 2010-10-14 トゥルビオン・ファーマシューティカルズ・インコーポレーテッド Ｃ末端に配置された特異的結合性ドメインを有する結合性ペプチド
PE20120259A1 (es) * 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
ES2368700T3 (es) * 2008-04-11 2011-11-21 Emergent Product Development Seattle, Llc Agente inmunoterapéutico para cd37 y combinación con un agente quimioterapéutico bifuncional del mismo.
RU2526156C2 (ru) * 2008-11-13 2014-08-20 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ, ЭлЭлСи Cd37-иммунотерапевтическая комбинированная терапия и ее применения

Also Published As

Publication number Publication date
CA2799036A1 (en) 2012-01-19
IL222775A0 (en) 2012-12-31
WO2012007576A1 (en) 2012-01-19
KR20130100918A (ko) 2013-09-12
NZ603161A (en) 2015-02-27
MX341463B (es) 2016-08-22
US20120189618A1 (en) 2012-07-26
EP2593479A1 (en) 2013-05-22
MX2012013613A (es) 2012-12-17
JP2017019800A (ja) 2017-01-26
US20130236454A1 (en) 2013-09-12
CL2013000101A1 (es) 2013-12-27
CN103003309A (zh) 2013-03-27
PH12013500118A1 (en) 2013-03-11
EA025365B1 (ru) 2016-12-30
EP3252077A1 (en) 2017-12-06
AU2011278227A1 (en) 2012-11-15
CN105749276A (zh) 2016-07-13
EA201201660A1 (ru) 2013-07-30
JP2013538790A (ja) 2013-10-17
US20150266967A1 (en) 2015-09-24
BR112013001012A2 (pt) 2016-05-24
IL222775A (en) 2017-10-31
AU2011278227B2 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
NZ703225A (en) Superior efficacy of cd37 antibodies in cll blood samples
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
HRP20181727T1 (hr) Upotreba protutijela protiv čimbenika xi, namijenjena sprečavanju ili liječenju stvaranja krvnog ugruška
MX2017016502A (es) Anticuerpos contra cd40 con actividad agonista mejorada.
NZ730763A (en) Methods of treating a tauopathy
PH12014500903A1 (en) Bispecific immunobinders directed against tnf and il-17
EA201400178A1 (ru) Лечение рака молочной железы
PH12013500277A1 (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
EA201171367A1 (ru) Винилиндазолильные соединения
EP2652506A4 (en) USE OF ANTIBODIES AGAINST CXCL16 AND CXCR6 FOR TREATMENT OR FOR THE DETECTION OF CANCER
WO2012078688A3 (en) Humanized antibodies to liv-1 and use of same to treat cancer
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
MA34091B1 (fr) Anticorps anti-cd40
EP2566890A4 (en) ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE
MX336001B (es) Anticuerpos anti-axl y metodos de uso.
AU2013216320A8 (en) C10RF32 Antibodies, And Uses Thereof For Treatment Of Cancer
MX347020B (es) Anticuerpo contra el csf-1r.
MY167920A (en) HUMAN ANTIBODIES TO GFRα3 AND METHODS OF USE THEREOF
WO2012173846A3 (en) Peptidomimetic macrocycles
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
EP4406550A3 (en) Antibodies to cd40 with enhanced agonist activity
WO2012082494A3 (en) The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer
PT2552963E (pt) Anticorpos anti cxcr4 humanizados para o tratamento de cancro

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 JUL 2018 BY SPRUSON + FERGUSON

Effective date: 20170316

LAPS Patent lapsed